NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the underwriter for its recent public offering has exercised an overallotment option to purchase 825,000 additional shares of the company's common stock, bringing the total gross proceeds from the offering to $31.6 million.

Aegis Capital was the sole book-running manager on the offering. Rosetta completed the public offering of 5.5 million shares at $5 per share earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.